Global Burn Care Market, by Product Type (Advanced Burn Care, Biologics, and Traditional Burn Care), by Burn Degree (First-Degree, Second-Degree, Third-Degree, and Other Degrees), by End User (Hospitals, Clinics and Burn Centers, Homecare, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 2,219.0 in 2018, and is projected to exhibit a CAGR of 6.1% over the forecast period (2019 - 2026), as highlighted in a new report published by . Technological advancements and increasing product approvals for the treatment of burns is expected to propel the burn care market growth over the forecast period. For instance, in September 2018, Avita Medical Americas LLC announced that the U.S. Food and Drug Administration (FDA) approved the company’s Premarket approval (PMA) application to market the RECELL Autologous Cell Harvesting Device (RECELL System) for the treatment of severe thermal burns in patients 18 years and older. The RECELL System uses a small amount of a patient’s own skin to prepare Spray-On Skin Cells at the point-of-care in as little as 30 minutes, providing a new way for the treatment of thermal burns. Other innovative techniques such as electrospinning technology is being widely adopted in burn care, which is further expected to propel growth of the burn care market. For instance, portable electrospinning technology enhances the inherent characteristics of electrospun nanofibers, mimicking the structure of the body tissue and thus, provides an excellent medium for tissue integration and regeneration and facilitates healing process in the body. Furthermore, several key market players are focused on development of new skin graft technologies, which is expected to drive the burn care market growth during the forecast period. For instance, in April 2019, Mallinckrodt Plc. announced that Stratatech, a Mallinckrodt company, completed patient enrollment in its ongoing pivotal Phase 3 clinical trial of StrataGraft, an investigational regenerative skin tissue. The multicenter study is evaluating the efficacy and safety of StrataGraft in the promotion of autologous skin regeneration of complex skin defects due to severe thermal burns that contain intact dermal elements (also known as deep partial-thickness burns). Browse 35 Market Data Tables and 23 Figures spread through 180 Pages and in-depth TOC on "Burn Care Market By Product Type (Advanced Burn Care, Biologics, and Traditional Burn Care), By Burn Degree (First-Degree, Second-Degree, Third-Degree, and Other Degrees), By End User (Hospitals, Clinics and Burn Centers, Homecare, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026" To know the latest trends and insights related to burn care market, click the link below: https://www.coherentmarketinsights.com/market-insight/burn-care-market-1279 Key players in the market are focused on launching technologically advanced products, which is expected to drive the market growth. For instance, in March 2018, Curam, a Science Foundation Ireland Research Center that designs medical devices, was involved in multidisciplinary healthcare approach, NanoGrowSkin Project to develop new advanced therapies and technologies in skin regeneration for the treatment of burns and chronic wounds. Key Takeaways of the Burn Care Market:
- The global burn care market is expected to witness a CAGR of 6.1% during the forecast period (2019–2026), owing to increasing technological advancements and regulatory approvals for burn care treatment
- Among product type, the advanced burn care segment is expected to account for major revenue share in 2026, owing increasing technological advances and increasing product approvals for the treatment of burns. For instance, in September 2018, AVITA Medical received the U.S. Food and Drug Administration approval for its RECELL, a regenerative skin-cell solution.
- Major players operating in the global burn care market include, Smith & Nephew Plc. Molnlycke, ConvaTec Inc., Integra LifeSciences Corporation, 3M, Coloplast A/S, Cardinal Health, Inc., DeRoyal Industries, Inc., Acelity Lp, and Svenska Cellulosa Aktiebolaget (SCA)
